With the introduction of cetuximab and panitumumab, two anti-epidermal growth factor receptor (EGFR)-targeted antibodies, the treatment of progressive colorectal cancer has entered the era of customized therapy [50]. This evidence concerns the gene EGFR and colorectal cancer.